Relief is finally on the horizon for countless dogs suffering from chronic itching and skin irritation across Europe. Elanco Animal Health Incorporated has just announced that Zenrelia™ (ilunocitinib), its once-daily oral treatment for allergic and atopic dermatitis in dogs, has been officially approved by the European Commission.

This green light from the EU marks a major turning point—not only for Elanco but for veterinarians and pet parents across the continent. Zenrelia, a JAK inhibitor designed specifically for canine dermatology, has already made waves in markets like the U.S., Brazil, Canada, and Japan. With this new approval, it’s poised to reshape how allergic skin conditions in dogs are managed in Europe.

Dr. Ellen de Brabander, Executive Vice President of Innovation and Regulatory Affairs at Elanco, called the EU approval “a pivotal achievement” that underscores both the safety and the impact of Zenrelia. “We’ve conducted rigorous clinical trials, including head-to-head comparisons with current market leaders. The results speak volumes—not just in controlled settings but in real-life situations where Zenrelia is already delivering relief to dogs,” she said.

Top IntentTech News: Emergence AI Launches CRAFT for Smarter Data Automation

What sets Zenrelia apart is its convenience and consistency. Administered just once a day, the tablet provides lasting relief from relentless itching and inflammation—an all-too-common problem for dogs with allergic or atopic dermatitis. And unlike some treatments that require frequent dosing or present compliance challenges, Zenrelia is easy for pet owners to use and well-tolerated by dogs as young as 12 months old.

The path to approval wasn’t without scientific rigor. As part of the EU regulatory process, Elanco led a large-scale, double-blind, randomized clinical study involving 338 client-owned dogs with confirmed atopic dermatitis. Spanning 25 veterinary sites across four European countries, the study compared Zenrelia directly with Apoquel, a longstanding leader in the market. By Day 28, Zenrelia had proven itself at least as effective as its competitor—a significant finding published in Veterinary Dermatology, one of the field’s top peer-reviewed journals.

Top IntentTech News: IPValue and Longitude License Semiconductor Patents to Samsung

According to Ramiro Cabral, Executive Vice President of Elanco International, the company’s commercial teams are already mobilizing to make the product available across Europe. “We’re not just bringing another treatment to market—we’re raising the bar for what veterinarians and pet parents can expect. Zenrelia is here to change the standard of care.”

Pet owners in Europe can expect to see Zenrelia available through veterinary channels before the end of Q3 this year, joining Elanco’s growing pet health lineup, which includes trusted names like AdTab, Credelio, and Galliprant.

For dogs suffering from relentless itching and discomfort—and for the humans who love them—Zenrelia offers more than just symptom control. It offers a promise of comfort, backed by science and delivered with care.

Top IntentTech News: Ireland Rail Upgrade to Boost Connectivity and Sustainability

To participate in our interviews, please write to our IntentTech Media Room at sudipto@intentamplify.com